Health Canada issues safety information on Vioxx, Celebrex, Bextra & Mobicox
Health Canada with their statement on the COX-2’s, adding Mobic to the warnings. Could be a harbinger of the FDA’s position.
ADVERTISEMENT
More in Uncategorized
Past Week
-
Evidence-based medicine vs. clinical judgment: a medical student’s perspective
-
The controversy over Maintenance of Certification for grandfathered physicians
-
How hindsight bias distorts clinical medicine
-
When side effects are actually a cry for help with medication costs
-
Proactive monitoring can prevent emergencies by catching heart signals early [PODCAST]
-
Why clinician education must prioritize nutrition training
-
Past 6 Months
-
The dangers of vertical integration in health care
-
Why does sex work seem like a more viable path than medicine in 2026?
-
The 9 laws of health care quality: Why metrics miss the point
-
Politics and fear have replaced science in U.S. pain management [PODCAST]
-
From Singapore to Canada: a blueprint for primary care transformation
-
How board certification fuels the physician shortage crisis
-
Recent Posts
-
Proactive monitoring can prevent emergencies by catching heart signals early [PODCAST]
-
Health care affordability crisis: lessons from the NYC nursing strike
-
How wearable technology is changing the role of physicians
-
Workplace violence against nurses: a crisis of systemic failure
-
Ignored DNR hospital policy: a family’s tragic end-of-life story
-
Why measuring muscle mass matters more than tracking your weight [PODCAST]
-
Subscribe to KevinMD and never miss a story!
Get free updates delivered free to your inbox.
